ANGLE plc

Prostate cancer ARV7 treatment biomarker

GUILDFORD, SURREY--(Marketwired - Jan 8, 2018) - (AIM: AG) (OTCQX: ANPCY)

For immediate release

8 January 2018

ANGLE plc ("the Company")

RESEARCH DEMONSTRATES USE OF PARSORTIX™ LIQUID BIOPSY TO DETECT ARV7 IN PROSTATE CANCER AS A TREATMENT SELECTION BIOMARKER

Parsortix-based ARV7 test may provide a wider understanding of ARV7 than other techniques with the potential for improved patient outcomes

Independent research estimates that an ARV7 test could save, on average, at least $5,000 per patient tested 

ANGLE plc (AIM: AGL) (OTCQX: ANPCY), a world-leading liquid biopsy company, is delighted to announce that the University Medical Centre Hamburg-Eppendorf (UKE) together with the Medical University of Graz (Graz) and the Science for Life Laboratory, Stockholm University (SciLifeLab) have published results of work demonstrating that ANGLE's Parsortix™ system can be used to measure the expression of ARV7 (androgen receptor splice variant 7) transcripts in later stage prostate cancer patients. 

The research has been published in Clinical Chemistry. A copy of the publication is available on ANGLE's website here https://angleplc.com/library/publications/.

Measurement of the expression of ARV7 on circulating tumor cells (CTCs) obtained from a blood test¹ has previously been studied and found to correlate with patient response to novel hormone therapy (NHT) drugs (Enzalutamide and Abiraterone). Where ARV7 is positively expressed, patients are unlikely to respond to NHT and benefit from moving directly to taxane-based chemotherapies. Where ARV7 is not expressed, patients do better when receiving NHT first and only moving to chemotherapy subsequently.

Researchers believe that an ARV7 test utilising the Parsortix system for CTC enrichment could provide key advantages over other approaches. These include:

• the ability to analyse mesenchymal CTCs, so called CK (cytokeratin) negative cells, which are not captured by other CTC systems. In their research, UKE, Graz and SciLifeLab found a population of CK negative ARV7 positive cells that would not have been detected with the other label-dependent enrichment methods tested.